

Brief Contents

PART 1: THE BASICS

- CHAPTER 1 General Pharmacologic Principles 3
- CHAPTER 2 The Metric System and Drug Dosage Calculations 35
- CHAPTER 3 Pharmacology of the Autonomic Nervous System 51
- CHAPTER 4 Medicated Aerosol Treatments 73

PART 2: THE SPECIFIC DRUG CATEGORIES

- CHAPTER 5 Bronchodilators 95
- CHAPTER 6 Mucokinetics and Surfactants 131
- CHAPTER 7 Anti-inflammatory and Antiasthmatic Agents 159
- CHAPTER 8 Antimicrobial Agents 187
- CHAPTER 9 Cardiac Agents 213
- CHAPTER 10 Blood Pressure and Antithrombotic Agents 241
- CHAPTER 11 Neuromuscular, Sedative, Anesthetic, and Analgesic Agents 269
- CHAPTER 12 Therapeutic Medical Gases 299

PART 3: PUTTING IT ALL TOGETHER

- CHAPTER 13 Pharmacologic Management of Obstructive Pulmonary Disease: Asthma, Chronic Bronchitis, and Emphysema 321
- CHAPTER 14 Pharmacologic Treatment of Respiratory Infectious Diseases 353
- CHAPTER 15 Medications for Emergency Cardiovascular Life Support 383

APPENDICES 411

GLOSSARY 415

INDEX 423

Contents

FOREWORD xiv

ACKNOWLEDGMENTS xv

PREFACE xvi

SUPPLEMENTS AND RESOURCES xviii

PREVIOUS EDITIONS' REVIEWERS xx

PART 1: THE BASICS

CHAPTER 1

General Pharmacologic Principles 3

- 1.1 Basic Terms 4
- 1.2 Drug Development 5
- 1.3 Herbal Supplements (Nutraceuticals) 6
- 1.4 Drug Information Sources 7
- 1.5 Interpreting Drug Information 7
 - 1.5a Drug Names 8
 - 1.5b Clinical Pharmacology 9
 - 1.5c Indications and Usage 9
 - 1.5d Contraindications 10
 - 1.5e Drug Interactions 11
 - 1.5f Adverse Drug Reactions 12
 - 1.5g Dosage and Administration 15
- 1.6 Routes of Administration 15
 - 1.6a Enteral Routes 17
 - 1.6b Parenteral Routes 17
 - 1.6c Other Routes 17
- 1.7 Pharmacokinetics 19
 - 1.7a Absorption 19
 - 1.7b Distribution 21
 - 1.7c Metabolism 22
 - 1.7d Elimination 23
- 1.8 Pharmacodynamics 24
 - 1.8a Selectivity 24
 - 1.8b Lock and Key Receptor Theory 25

- 1.8c Racemic Mixtures 26
- 1.8d Agonists versus Antagonists 26
- 1.8e Potency 26
- 1.8f Tolerance 27
- 1.8g Half-Life 28
- 1.8h Poisoning and Toxicity 29

1.9 Pharmacogenomics 29

1.10 Prescription Orders 30

1.11 Commonsense Rules 32

Summary 33

Review Questions 33

CHAPTER 2

The Metric System and Drug Dosage Calculations 35

- 2.1 Exponential Powers of 10 36
 - 2.1a Exponents 36
- 2.2 Systems of Measurement 38
 - 2.2a United States Customary System 38
 - 2.2b The Metric System 38
 - 2.2c Example Calculation 1 39
 - 2.2d Example Calculation 2 39
 - 2.2e Conversion of Units 41
 - 2.2f Example Calculation 3 41
 - 2.2g Example Calculation 4 42
 - 2.2h Factor-Label Method to Convert between Systems 42
 - 2.2i Example Calculation 5 42
 - 2.2j Example Calculation 6 42

- 2.3 Drug Dosage Calculations 43
 - 2.3a Solutions 43
 - 2.3b Percentage Solutions 44
 - 2.3c Setting Up Proportions 45
 - 2.3d Example Calculation 7 45
 - 2.3e Example Calculation 8 46
 - 2.3f Example Calculation 9 46
 - 2.3g Ratio Solutions 47
 - 2.3h Drug Orders in Drops 48

Summary 49

Review Questions 49

CHAPTER 3

Pharmacology of the Autonomic Nervous System 51

- 3.1 Nervous System Divisions 52
 - 3.1a PNS Divisions 53
- 3.2 Nervous System Conduction 57
 - 3.2a Types and Location of Neurotransmitters 57
 - 3.2b Receptors 59
 - 3.2c Receptor Classification 61
- 3.3 ANS Drug Terminology 62
 - 3.3a Direct- and Indirect-Acting Agents 64
 - 3.3b Parasympathomimetics 64
 - 3.3c Parasympatholytics 65
 - 3.3d Sympathomimetics 66
 - 3.3e Sympatholytics 69

Summary 70

Review Questions 70

CHAPTER 4

Medicated Aerosol Treatments 73

- 4.1 Basic Concepts of Medicated Aerosols 74
 - 4.1a What Is Aerosol Therapy? 74
 - 4.1b Advantages and Disadvantages 75
 - 4.1c Technical Background 76
 - 4.1d Aerosol Size Matters 77
 - 4.1e Breathing Pattern 78
 - 4.1f Types of Aerosolized Drugs 79

- 4.2 Aerosol Delivery Devices 80
 - 4.2a Metered-Dose Inhaler 80
 - 4.2b Small-Volume Nebulizer 84
 - 4.2c Other Nebulizer Designs 84
 - 4.2d Continuous Bronchodilator Therapy 85
 - 4.2e Dry Powder Inhaler 86
 - 4.2f Choosing the Appropriate Delivery Device 87
 - 4.2g Aerosol Delivery in Intubated Patients 88

4.3 The Future 90

Summary 91

Review Questions 91

Case Study 4–1: Mr. Blue 92

PART 2: THE SPECIFIC DRUG CATEGORIES

CHAPTER 5

Bronchodilators 95

- 5.1 Airway Anatomy and Physiology 96
 - 5.1a Bronchoconstriction versus Bronchospasm 97
- 5.2 Neurological Control of Bronchial Smooth Muscle 99
 - 5.2a Sympathetic Nervous System 99
 - 5.2b Parasympathetic Nervous System 99
 - 5.2c Chemical Mediators of Neural Transmission 100
 - 5.2d Sympathetic Nervous System Receptors 102
 - 5.2e The Sympathetic Nervous System in the Lung 102
- 5.3 Bronchodilators 103
 - 5.3a Sympathomimetic (Adrenergic) Bronchodilators 105
 - 5.3b Mechanism of Action 105
- 5.4 Development of the β -Agonists 106
 - 5.4a Catecholamines 108
 - 5.4b Resorcinols 108
 - 5.4c Saligenins 109
 - 5.4d Side Effects of β -Agonists 114



- 5.4e Classification by Duration of Action 116
- 5.5 Anticholinergic (Parasympatholytic) Bronchodilators 118
 - 5.5a Mechanism of Action 119
 - 5.5b Atropine Sulfate 120
 - 5.5c Ipratropium Bromide (Atrovent®) 121
 - 5.5d Tiotropium Bromide (Spiriva®) 122
 - 5.5e Monitoring Outcomes of Inhaled Bronchodilator Therapy 125
- 5.6 Methylxanthines 127
 - 5.6a Mechanism of Action 127
 - 5.6b Nonbronchodilating Effects of Theophylline 127

Summary 126

Review Questions 126

Case Study 5–1: A 66-year-old male 128

Case Study 5–2: A 9-year-old boy 128

Case Study 5–3: A patient with COPD 129

CHAPTER 6

Mucokinetics and Surfactants 131

- 6.1 The Mucociliary System 132
 - 6.1a Anatomy and Physiology 132
 - 6.1b Structure and Composition of Mucus 133
- 6.2 Bland Aerosols 137
 - 6.2a Definitions 137
 - 6.2b Delivery Methods 137
 - 6.2c Bland Solutions 139
- 6.3 Mucolytics 141
 - 6.3a Definition 141
 - 6.3b Expectorants 144
 - 6.3c Antitussives/Cough Suppressants 144
 - 6.3d Conclusion 145
- 6.4 Surface-Active Agents 145
 - 6.4a Alveolar Physiology and Surfactant Synthesis 145
 - 6.4b Surfactant Function 147
 - 6.4c Indications for Surfactant Replacement Therapy 150

- 6.4d Types of Exogenous Surfactants 150
- 6.4e Therapeutic Approaches 150
- 6.4f Representative Drugs 151
- 6.4g General Techniques of Surfactant Administration 151
- 6.4h Adverse Reactions 152
- 6.4i Surfactant Administration in Adult Patients 154

Summary 155

Review Questions 155

Case Study 6–1: A COPD patient 157

Case Study 6–2: A baby boy 157

CHAPTER 7

Anti-inflammatory and Antiasthmatic Agents 159

- 7.1 The Inflammatory Process 160
 - 7.1a The Immune Response 160
 - 7.1b Mast Cell Chemical Mediator Release 161
 - 7.1c Types of Asthma 163
 - 7.1d Phases of the Inflammatory Response 163
- 7.2 Corticosteroids 165
 - 7.2a Corticosteroid Physiology 165
 - 7.2b Hypothalamic-Pituitary-Adrenal Axis 167
 - 7.2c Corticosteroid Mechanism of Action 168
 - 7.2d Corticosteroid Use in Airway Remodeling 169
 - 7.2e Adverse Effects of Corticosteroids 169
 - 7.2f Oral and Parenteral Corticosteroid Administration 170
 - 7.2g Inhaled Corticosteroids 170
 - 7.2h Benefits of Daily Corticosteroid Use 173
 - 7.2i Steroid Dependency 175
- 7.3 Antiasthmatics 175
 - 7.3a Cromolyn Sodium 175
 - 7.3b Dosage Forms 176
 - 7.3c Side Effects 176

- 7.4 Prostaglandins 176
 - 7.4a Physiology 176
- 7.5 Leukotriene Modifiers 177
 - 7.5a Physiology 177
- 7.6 Antiasthmatic Monoclonal Antibody 178
 - 7.6a Physiology 178
- 7.7 Treating Upper Airway Congestion 178
 - 7.7a Allergic Rhinitis 178
 - 7.7b Intranasal Medications 179
 - 7.7c Antihistamines 180
 - 7.7d Decongestants 183

Summary 184

Review Questions 184

Case Study 7–1: A 24-year-old woman 185

CHAPTER 8

Antimicrobial Agents 187

- 8.1 General Principles of Anti-infective Therapy 188
 - 8.1a Terminology 188
 - 8.1b The Infection Process 189
 - 8.1c Empiric Therapy 189
 - 8.1d Classification of Bacteria 190
 - 8.1e Identification of Pathogenic Organisms 191
 - 8.1f Mechanisms of Resistance 194
 - 8.1g Monitoring Anti-infective Therapy 195
- 8.2 Classification of Antibacterial Agents 196
 - 8.2a Bacteriostatic versus Bactericidal 196
 - 8.2b Broad-Spectrum versus Narrow-Spectrum 196
 - 8.2c Based on Mechanism of Action 197
 - 8.2d Antibacterial Agents 197
- 8.3 Antivirals 204
 - 8.3a Antivirals to Treat Herpes 205
 - 8.3b Antivirals to Treat Respiratory Syncytial Virus 206

- 8.3c Antivirals to Treat Acquired Immunodeficiency Syndrome (AIDS) 207

8.4 Antifungals 208

Summary 210

Review Questions 210

Case Study 8–1: A 68-year-old man 211

CHAPTER 9

Cardiac Agents 213

- 9.1 Cardiovascular Overview 215
 - 9.1a Basic Terminology 215
 - 9.1b Cardiac Circulation 215
 - 9.1c Cardiac Conduction 217
 - 9.1d Ion Influence 218
 - 9.1e The ECG Tracing 219
 - 9.1f Arrhythmias 220
 - 9.1g Sites of Arrhythmias 221
- 9.2 Antiarrhythmic Agents 222
 - 9.2a Therapeutic Goals 222
 - 9.2b Mechanism of Action 222
 - 9.2c Classification of Antiarrhythmic Drugs 222
- 9.3 Heart Failure 224
 - 9.3a Pathophysiology 224
 - 9.3b Drugs to Treat Heart Failure 225
 - 9.3c Digoxin for Heart Failure 225
 - 9.3d ACE Inhibitors for Heart Failure 226
 - 9.3e ARBs for Heart Failure 227
 - 9.3f Angiotensin Receptor Neprilysin Inhibitor 227
 - 9.3g β -Antagonists for Heart Failure 227
 - 9.3h Vasodilators for Heart Failure 228
 - 9.3i Diuretics for Heart Failure 228
 - 9.3j Aldosterone Antagonists for Heart Failure 229
 - 9.3k Intravenous Inotropes for Heart Failure 229
 - 9.3l Dopamine for Heart Failure 230



- 9.3m Nitroprusside for Heart Failure 230
- 9.3n Nitroglycerin for Heart Failure 230
- 9.3o Nesiritide for Heart Failure 230
- 9.4 Management of Shock 231
- 9.5 Angina 231
 - 9.5a Pathophysiology of Angina 231
 - 9.5b Pharmacologic Treatment of Angina 231
 - 9.5c β -Blockers as Antianginals 232
 - 9.5d Calcium Channel Blockers as Antianginals 233
 - 9.5e Nitroglycerin as an Antianginal 234
 - 9.5f Ranolazine 234
- 9.6 Acute Coronary Syndromes 234
 - 9.6a Myocardial Infarction 235
 - 9.6b Diabetes Mellitus 235
 - 9.6c Classes of Diabetes Drugs 236
 - 9.6d Lipid-Lowering Agents 237
- 10.2e Angiotensin-Converting Enzyme Inhibitors (ACEIs) 253
- 10.2f Angiotensin II Receptor Blockers (ARBs) 254
- 10.2g Calcium Channel Blockers 255
- 10.2h Vasodilators 255
- 10.2i Agents for Hypertensive Emergencies/Urgencies 256
- 10.2j Treating Hypotension 258
- 10.3 The Hemostatic System 259
 - 10.3a The Clotting Process 259
 - 10.3b Anticoagulants 260
 - 10.3c Direct Thrombin Inhibitors 263
 - 10.3d Antiplatelet Drugs 264
 - 10.3e Platelet Glycoprotein IIb/IIIa Receptor Inhibitors 265
 - 10.3f Fibrinolytics 265

Summary 239

Review Questions 239

Case Study 9–1: An elderly female 240

CHAPTER 10

Blood Pressure and Antithrombotic Agents 241

- 10.1 Blood Pressure 242
 - 10.1a The Basics 242
 - 10.1b Blood Vessels 243
 - 10.1c Regulation of Blood Pressure 244
 - 10.1d Hypertension 244
- 10.2 Categories of Drugs to Treat Hypertension 248
 - 10.2a Direct-Acting α_2 -Agonists or Central-Acting Sympatholytics 248
 - 10.2b α_1 -Blockers or Peripheral-Acting Sympatholytics 249
 - 10.2c β -Blockers 249
 - 10.2d Diuretics 250

Summary 267

Review Questions 267

Case Study 10–1: An obese 75-year-old woman 268

CHAPTER 11

Neuromuscular, Sedative, Anesthetic, and Analgesic Agents 269

- 11.1 Nerve Transmission 271
 - 11.1a Physiology of Muscle Contraction 271
 - 11.1b Acetylcholinesterase 272
 - 11.1c Neuromuscular Blocking Agents 272
 - 11.1d Nondepolarizing Agents 273
 - 11.1e Depolarizing Agents 273
 - 11.1f NMBA Selection Factors 274
- 11.2 Skeletal Muscle Relaxants 277
- 11.3 Sedatives, Hypnotics, and Anxiolytics 278
 - 11.3a Terminology 278
 - 11.3b Benzodiazepines 278
 - 11.3c α_2 -Adrenergic Agonist (Sedative) 279
 - 11.3d Nonbenzodiazepines 279
 - 11.3e Barbiturates 279
 - 11.3f Conscious Sedation 280

- 11.4 Anesthetics 280
 - 11.4a General versus Local 280
 - 11.4b General Anesthesia 280
 - 11.4c Stages of Anesthesia 281
 - 11.4d Specific General Anesthetics 281
 - 11.4e Local Anesthetics 283
 - 11.4f Postoperative Nausea and Vomiting 284
- 11.5 Ventilatory Stimulants 285
- 11.6 Analgesia 286
 - 11.6a Principles of Analgesia 286
 - 11.6b The Pain Response 287
 - 11.6c Analgesics 288
 - 11.6d Outcomes Assessment Analgesic Therapy 288
 - 11.6e Pain-Related Terminology 288
 - 11.6f Classes of Analgesics 289
 - 11.6g Opioids 289
 - 11.6h Opioid Antagonists 291
 - 11.6i Corticosteroids 292
 - 11.6j Nonsteroidal Anti-inflammatory Agents 293
 - 11.6k Analgesic Synergy 294
 - 11.6l Adjuncts to Analgesics 295

Summary 296

Review Questions 296

CHAPTER 12

Therapeutic Medical Gases 299

- 12.1 Oxygen Therapy 300
 - 12.1a Physiologic Background 300
 - 12.1b Hypoxemia 301
 - 12.1c Clinical Manifestations of Hypoxemia 303
 - 12.1d Hypoxia 303
 - 12.1e Goals of Oxygen Therapy 304
 - 12.1f Oxygen Administration Devices 305
 - 12.1g Monitoring Oxygen Therapy 310
 - 12.1h Hazards of Oxygen Therapy 311

- 12.2 Helium Therapy 312
 - 12.2a Indications for Helium Therapy 312
 - 12.2b Administration of Helium-Oxygen 313
 - 12.2c Hazard of Helium-Oxygen Therapy 313
- 12.3 Nitric Oxide Therapy 313
 - 12.3a Physiology of Nitric Oxide 314
 - 12.3b iNO Administration and Dosage 314
 - 12.3c Therapeutic Indications for Inhalation of Nitric Oxide 314
 - 12.3d Monitoring Nitric Oxide Therapy 315

Summary 316

Review Questions 316

Case Study 12-1: A 68-year-old woman 317

PART 3: PUTTING IT ALL TOGETHER

CHAPTER 13

Pharmacologic Management of Obstructive Pulmonary Disease: Asthma, Chronic Bronchitis, and Emphysema 321

- 13.1 Asthma 323
 - 13.1a Background 323
 - 13.1b Differential Diagnosis 324
 - 13.1c Asthma Symptoms 325
 - 13.1d Asthma Treatment Goals 328
 - 13.1e Classification of Asthma Severity 328
 - 13.1f Asthma Medications 329
 - 13.1g Asthma Management 332
 - 13.1h Management of Acute Asthma Exacerbations 334
- 13.2 COPD 337
 - 13.2a Background 337
 - 13.2b Etiology 337
 - 13.2c Prevention: The Key to Treatment of COPD 339
 - 13.2d COPD Treatment Goals 344



- 13.2e Assessment of COPD 344
- 13.2f Drugs Used to Treat COPD 345
- 13.2g Step-by-Step Approach 349

Summary 351

Review Questions 351

Case Study 13–1: A 25-year-old man 352

CHAPTER 14

Pharmacologic Treatment of Respiratory Infectious Diseases 353

- 14.1 Developing a Therapeutic Plan for Respiratory Infectious Diseases 355
 - 14.1a Empiric Treatment 355
 - 14.1b Local Resistance Patterns (the Antibigram) 356
 - 14.1c Individualizing Therapy 356
- 14.2 Upper Airway Infectious Diseases 358
 - 14.2a Otitis Media 358
 - 14.2b Sinusitis 362
 - 14.2c Pharyngitis 364
- 14.3 Other Upper Airway Infections 367
 - 14.3a Epiglottitis 367
 - 14.3b Croup 367
- 14.4 Lower Respiratory Tract Infections 368
 - 14.4a Acute Bronchitis and Bronchiolitis 368
 - 14.4b Pneumonia 370
 - 14.4c Tuberculosis 378
 - 14.4d Avian Influenza 380
- 14.5 Chemical Terrorism 380
- Chemical Terrorism 380
- Summary** 381
- Review Questions** 381
- Case Study 14–1:** A 60-year-old man 382

CHAPTER 15

Medications for Emergency Cardiovascular Life Support 383

- 15.1 Normal Conduction and Arrhythmias 385
 - 15.1a Electrophysiology 385

- 15.1b Normal Conduction 386
- 15.1c Acute Myocardial Infarction 387
- 15.1d Bradycardia 388
- 15.1e Tachycardia 388
- 15.1f Ventricular Fibrillation 390
- 15.1g Asystole 390
- 15.1h Pulseless Electrical Activity 391

- 15.2 Pharmacologic Agents for Advanced Life Support 392
 - 15.2a Medication Access 392
 - 15.2b Categories of ACLS Drugs 392
- 15.3 Medications for Cardiovascular Support 393
 - 15.3a Oxygen 393
 - 15.3b Epinephrine 394
 - 15.3c Vasopressin 395
 - 15.3d Norepinephrine 396
 - 15.3e Sodium Bicarbonate 396
- 15.4 Positive Inotropic Drugs 397
 - 15.4a Digoxin 397
 - 15.4b Milrinone 398
 - 15.4c Dopamine 398
 - 15.4d Dobutamine (Dobutrex®) 399
- 15.5 Antiarrhythmic Drugs 399
 - 15.5a Atropine 399
 - 15.5b Amiodarone (Cordarone®) 400
 - 15.5c Lidocaine 401
 - 15.5d Procainamide (Pronestyl®) 402
 - 15.5e Magnesium Sulfate 402
 - 15.5f Ibutilide (Corvert®) 403
- 15.6 Calcium Channel Blockers 403
 - 15.6a Verapamil (Calan®, Isoptin®) 404
 - 15.6b Diltiazem (Cardizem®) 404
 - 15.6c Adenosine (Adenocard®) 405
 - 15.6d β -Adrenergic Blockers 406
 - 15.6e Sotalol (Betapace®) 407

Review Questions 408

Case Study 15–1: A 67-year-old woman 409

APPENDICES 411

GLOSSARY 415

INDEX 423